Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Track all the latest updates and news of Concord Biotech IPO.
April 18, 2024 6:17:00 PM
Apr 18, 2024 14:36 Source: BSE Concord Biotech - Certificate Under Regulation 40(9) Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations, 2015 Pursuant to Regulation 40(9 ...
Published by : moneycontrol.comApril 23, 2024 7:30:15 PM
Biotech IPOs surged at the start of 2024, but the rest of the year will depend on Fed rate cuts. Meanwhile, doctors using VR and AI to hone their skills.
Published by : CNBC on MSNMay 3, 2024 6:53:00 PM
CG Oncology�s late-stage bladder cancer treatment notched a complete response in roughly three-quarters of treated patients, fueling optimism that the company�s Wall Street success story is no fluke.
Published by : FierceBiotechApril 29, 2024 7:21:00 PM
Concord Biotech Ltd share price was down by -0.58% from the previous closing price of ?1,660.05. Who are peers of Concord Biotech Ltd? The peers of Concord Biotech Ltd are Sun Pharmaceuticals ...
Published by : Business TodayMay 3, 2024 2:20:00 PM
Delegates at the LSX World Conference in London this week seemed to agree on one thing�the biotech IPO window finally re-opened this year. This sentiment has persisted despite the fact that the ...
Published by : FierceBiotechApril 25, 2024 8:21:00 AM
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Published by : InvestingMay 6, 2024 6:19:00 PM
Eccogene, a Boston and Shanghai biotech working on an oral GLP-1 candidate with AstraZeneca, is considering an initial public offering early next year, CEO Jingye Zhou told Endpoints News. The company ...
Published by : ENDPOINTS NEWSApril 11, 2024 12:30:00 PM
its intersecting role in the biotech sector has been a boon for industry � making biotech IPOs more coveted this year. Klarna European fintech darling Klarna was once the continent's highest ...
Published by : Business InsiderApril 12, 2024 10:33:00 AM
The sum is more than three times the $375 million in total proceeds from biotech IPOs in the first quarter last year, and roughly matches the first quarter total in 2020. Six of the nine biotechs ...
Published by : Yahoo FinanceApril 10, 2024 11:07:00 AM
It�ll begin trading on the Nasdaq stock exchange on Friday under the symbol �CTNM.� Contineum�s offering keeps biotech IPOs on their strongest pace in three years, according to BioPharma Dive data. By ...
Published by : Yahoo FinanzasApril 23, 2024 3:29:00 AM
But it's too early to say that the biotech IPO market has fully recovered. Biotech IPOs appeared to reach pre-pandemic levels during the first quarter, with nine companies collectively raising ...
Published by : NBC Bay AreaThe IPO Shares of Concord Biotech Limited IPO are proposed to list on Friday, August 18, 2023 at BSE, NSE. The public issue of Concord Biotech IPO was opened on Aug 4, 2023 and closed for subscription on Aug 8, 2023. Concord Biotech IPO Listing Date and Information:
| Listing Date | Friday, August 18, 2023 |
| BSE Script Code | 543960 |
| NSE Symbol | CONCORDBIO |
| Listing In | |
| ISIN | INE338H01029 |
| Issue Price | ₹741 Per Equity Share |
| Face Value | ₹1 Per Equity Share |
The allotment status of Concord Biotech Limited IPO is now available online. The public issue of Concord Biotech IPO was open on Aug 4, 2023 and closed for subscription on Aug 8, 2023. The equity shares of the company to be list at BSE, NSE
.
Concord Biotech Limited is entering in the capital market with an IPO of 20,925,652 Equity Shares of Rs 1 aggregating up to Rs 1,551.00 Crore. The price for the issue has been set at Rs 705 - Rs 741 Per Equity Share.
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company. The company is ranked among the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022.
The issue opens on Aug 4, 2023 and closes for subscription on Aug 8, 2023. The equity shares of the company to be list at BSE, NSE.
The issue of Concord Biotech Limited opens on Aug 4, 2023 and closes for subscription on Aug 8, 2023. The equity shares of the company to be list at BSE, NSE. The price for the issue has been set at Rs 705 - Rs 741 Per Equity Share.
The Concord Biotech IPO is proposed to open on August 4, 2023. The IPO application ends on August 8, 2023.
Retail investors can apply in the retail or non-institutional investor category from August 4, 2023 to August 8, 2023. The Concord Biotech IPO can be applied online through Net Bank (ASBA method) or the stock broker (UPI method).
The Concord Biotech IPO will open for subscription on August 4, 2023. The public issue will close on August 8, 2023.
Useful Articles
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
